Atherosclerosis: Open Access
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Review Article   
  • Atheroscler Open Access 2023, Vol 8(4): 218
  • DOI: 10.4172/asoa.1000218

Atherosclerosis: Targeting LDL Cholesterol with Statins and PCSK9 Inhibitors for Cardiovascular Disease Management

Christie Stewart*
Department of Neurology and Stroke Program, University of Miami, United States
*Corresponding Author : Christie Stewart, Department of Neurology and Stroke Program, University of Miami, United States, Email: c.stewart@gmail.com

Received Date: Jun 28, 2023 / Accepted Date: Jul 26, 2023 / Published Date: Jul 27, 2023

Abstract

Atherosclerosis is a complex and chronic inflammatory disease that affects large and medium-sized arteries, leading to severe cardiovascular complications such as ischemic heart disease, strokes, and peripheral vascular disease collectively known as cardiovascular disease (CVD). This review article provides an overview of atherosclerosis, its pathophysiology, and the role of elevated LDL (low-density lipoprotein) cholesterol in its development. Furthermore, it examines the therapeutic options of statins and PCSK9 inhibitors, which have shown significant promise in managing LDL cholesterol levels and reducing major adverse cardiovascular events.

Citation: Stewart C (2023) Atherosclerosis: Targeting LDL Cholesterol with Statins and PCSK9 Inhibitors for Cardiovascular Disease Management. Atheroscler Open Access 8: 218. Doi: 10.4172/asoa.1000218

Copyright: © 2023 Stewart C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top